Discontinued — last reported Q4 '25

Debt Issuance Proceeds

Financing

Eli Lilly Debt Issuance Proceeds decreased by 100.0% to $0.00 in Q4 2025 compared to the prior quarter. Over 3 years (FY 2021 to FY 2025), Debt Issuance Proceeds shows an upward trend with a 76.1% CAGR.

Analysis

StatementCash Flow Statement
SectionFinancing
CategoryLeverage
SignalContext dependent
VolatilityVolatile
First reportedQ1 2014
Last reportedQ4 2025

How to read this metric

High issuance can signal expansion plans or a strategy to take advantage of low interest rates, but also increases future interest obligations.

Detailed definition

The total cash proceeds received from the sale of bonds, notes, or other debt instruments. This represents an increase i...

Peer comparison

Companies often issue debt even when they have cash to optimize their weighted average cost of capital (WACC).

Metric ID: cf_debt_issuance

Historical Data

17 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$602.70M$602.70M$602.70M$0.00$0.00$3.96B$0.00$0.00$0.00$6.45B$0.00$4.96B$0.00$6.46B$0.00$6.71B$0.00
QoQ Change+0.0%+0.0%-100.0%-100.0%-100.0%-100.0%-100.0%-100.0%
YoY Change-100.0%+63.0%+0.1%+35.1%
Range$0.00$6.71B
CAGR-100.0%
Avg YoY Growth-0.4%
Median YoY Growth+17.6%

Frequently Asked Questions

What is Eli Lilly's debt issuance proceeds?
Eli Lilly (LLY) reported debt issuance proceeds of $0.00 in Q4 2025.
What is the long-term trend for Eli Lilly's debt issuance proceeds?
Over 3 years (2021 to 2025), Eli Lilly's debt issuance proceeds has grown at a 76.1% compound annual growth rate (CAGR), from $2.41B to $13.17B.
What does debt issuance proceeds mean?
The amount of new money a company borrowed by issuing bonds or taking out loans.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.